6533b838fe1ef96bd12a50fe

RESEARCH PRODUCT

Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment

Giuseppe ColellaGiuseppina CampisiAnastasios LoidorisVittorio FuscoPaolo Vescovi

subject

Oncologymedicine.medical_specialtyBreast Neoplasmszoledronic acidBreast cancerSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineHumansBone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawbusiness.industryImidazolesOsteonecrosisGeneral Medicinemedicine.diseaseosteonecrosis jawsZoledronic acidJawbreast cancer patientsFemaleSurgerybusinessOsteonecrosis of the jawmedicine.drug

description

The importance of adoption of recommendations for ONJ prevention strategy will notably grow for zoledronic acid in the next future, in view of possible further enlargement of its indications (even with different timing and schedules) in breast cancer patients without bone metastases (such as in adjuvant and neo-adjuvant settings, and in hormonotherapy-induced osteopenia

yearjournalcountryeditionlanguage
2010-01-01The Breast
https://doi.org/10.1016/j.breast.2010.03.008